en POLSKI
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
6/2019
vol. 94
 
Share:
Share:
abstract:
Case report

The impact of primary varicella zoster virus infection on delay in diagnosis and treatment of neoplastic diseases in children – case reports

Karolina Pogorzelska
1
,
Małgorzata Sawicka-Żukowska
1
,
Agnieszka Kania
1
,
Maryna Krawczuk-Rybak
1

  1. Department of Pediatric Oncology and Hematology, Medical University of Bialystok, Bialystok, Poland
Pediatr Pol 2019; 94 (6): 388–392
Online publish date: 2019/12/31
View full text Get citation
 
PlumX metrics:
Primary varicella zoster virus (VZV) infection is highly contagious and life-threatening in immunocompromised patients. Children treated for neoplastic disease are at increased risk of severe illness and fatal outcomes. Varicella zoster infection (VZI) may cause diagnostic difficulties and result in the delay in anticancer therapy. We present the cases of four children diagnosed with neoplastic diseases and chickenpox infection simultaneously. Two patients were diagnosed with acute lymphoblastic leukaemia (ALL), one with acute myeloblastic leukaemia (AML), and one with Wilms tumour. Initially all patients received targeted and symptomatic treatment against VZV infection, and then they were reassigned to chemotherapeutic treatment. Three children received intravenous acyclovir for seven days, and one received oral treatment. The patient diagnosed with Wilms tumour, after receiving actinomycin-D, developed veno-occlusive disease with a very acute course. Mean delay in chemotherapy due to VZI was eight days. None of the patients died as a result of the infection or oncological disease.
keywords:

chickenpox, acute leukaemia, childhood cancer, VZV

 
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.